Yu Xin, Li Zheng, Yu Jun, Chan Matthew T V, Wu William K K
Department of Orthopaedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100042, China.
State-Key Laboratory of Digestive Diseases, LKS Institute of Health Sciences and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, 999077, China.
Cell Prolif. 2015 Oct;48(5):503-10. doi: 10.1111/cpr.12202. Epub 2015 Jul 22.
Colorectal cancer (CRC) is the fourth leading cause of cancer-related death globally. Chemotherapy regimens consisting of 5-fluorouracil (5-FU) in combination with either oxaliplatin or irinotecan are the first-line options for treatment of metastatic CRC. However, primary or acquired resistance to these chemotherapeutics is a major clinical challenge. MicroRNAs (miRNAs) are a group of small non-coding RNAs that regulate gene expression post-transcriptionally. miRNAs play important roles in many cancer-related processes, including cell proliferation, apoptosis and invasion, and their dysregulation is implicated in colorectal tumourigenesis. Pertinent to chemotherapy, increasing evidence has revealed that miRNAs can be directly linked to chemosensitivity in CRC. In this review, we summarize current evidence concerning the role of miRNAs in prediction and modulation of cellular responses to 5-FU, oxaliplatin and irinotecan in CRC. We also discuss the possible targets and intracellular pathways involved in these processes.
结直肠癌(CRC)是全球癌症相关死亡的第四大主要原因。由5-氟尿嘧啶(5-FU)联合奥沙利铂或伊立替康组成的化疗方案是转移性CRC治疗的一线选择。然而,对这些化疗药物的原发性或获得性耐药是一个主要的临床挑战。微小RNA(miRNA)是一组小的非编码RNA,它们在转录后调节基因表达。miRNA在许多癌症相关过程中发挥重要作用,包括细胞增殖、凋亡和侵袭,其失调与结直肠癌的发生有关。与化疗相关的是,越来越多的证据表明,miRNA可直接与CRC中的化疗敏感性相关。在本综述中,我们总结了关于miRNA在预测和调节CRC细胞对5-FU、奥沙利铂和伊立替康反应中的作用的当前证据。我们还讨论了这些过程中可能涉及的靶点和细胞内途径。